Lucid Diagnostics Inc (NAS:LUCD)

Q1 2025 Lucid Diagnostics Inc Earnings Call Transcript

May 14, 2025 / 12:30 PM GMT

Release Date Price: $1.28 (+7.56%)

Transcript 8-K10-Q

Key Points

Positve

Lucid Diagnostics Inc (LUCD) performed 3,034 e-cigar tests in Q1, reaching the upper end of their target range.
The company secured approximately $16.1 million in proceeds from a public offering, strengthening their balance sheet.
They have doubled the number of contracts in their concierge medicine program, indicating growth in this area.
Lucid Diagnostics Inc (LUCD) has a successful partnership with a major health system for a comprehensive esophageal pre-cancer testing program.
The company is optimistic about imminent Medicare coverage for their Eoguard test, which could significantly boost commercialization efforts.

Negative

Revenue of $800,000 fell short due to external headwinds and a greater concentration of testing through healthcare events.
There were delays in cash collections from UnitedHealthcare due to a national issue with their new system for molecular pathology claims.
The quarterly burn rate was $11.3 million, slightly higher than the average for the preceding four quarters.
The effective average selling price (ASP) declined quarter over quarter, partly due to mix and reimbursement challenges.
The company faces challenges in securing reimbursement from Kaiser and other insurers, impacting revenue recognition.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LUCD.OQ - Lucid Diagnostics Inc
Q1 2025 Lucid Diagnostics Inc Earnings Call
May 14, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to the Lucid Diagnostics first quarter 2025 business update conference call.

Please note this event is being recorded. I would now like to turn the conference call over to Mr. Matt Riley, Lucid Diagnostics senior director of investor relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Good morning, everyone.

Thank you for participating in today's business update call. Joining me today on the call, Doctor Leshan Acog, Chairman and Chief Executive Officer of Lucid Diagnostics, along with

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.